These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 24669013

  • 1. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II.
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [Abstract] [Full Text] [Related]

  • 2. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [Abstract] [Full Text] [Related]

  • 3. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L.
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [Abstract] [Full Text] [Related]

  • 4. SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T, Lee D, Wu L, Patel P, Young AJ, Wada H, Hu HP, Ujiie H, Kaji M, Kano S, Matsuge S, Domen H, Kanno H, Hatanaka Y, Hatanaka KC, Kaga K, Matsui Y, Matsuno Y, De Perrot M, Yasufuku K.
    Int J Oncol; 2016 Dec; 49(6):2411-2420. PubMed ID: 27840913
    [Abstract] [Full Text] [Related]

  • 5. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [Abstract] [Full Text] [Related]

  • 6. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G.
    J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
    [Abstract] [Full Text] [Related]

  • 7. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
    Dong L, Jensen RV, De Rienzo A, Gordon GJ, Xu Y, Sugarbaker DJ, Bueno R.
    BMC Med Genet; 2009 Dec 31; 10():149. PubMed ID: 20043850
    [Abstract] [Full Text] [Related]

  • 8. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D.
    Clin Cancer Res; 2014 Mar 01; 20(5):1323-34. PubMed ID: 24443521
    [Abstract] [Full Text] [Related]

  • 9. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.
    Mol Cancer; 2016 Jun 01; 15(1):44. PubMed ID: 27245839
    [Abstract] [Full Text] [Related]

  • 10. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
    Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, Bueno R.
    Am J Pathol; 2005 Jun 01; 166(6):1827-40. PubMed ID: 15920167
    [Abstract] [Full Text] [Related]

  • 11. MicroRNAs dysregulation in human malignant pleural mesothelioma.
    Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, Martini F, Tognon MG.
    J Thorac Oncol; 2011 May 01; 6(5):844-51. PubMed ID: 21358347
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, Yang CT, Huang Z, You J, Xu Z, Jablons DM, You L.
    J Cell Mol Med; 2018 Jun 01; 22(6):3139-3148. PubMed ID: 29575535
    [Abstract] [Full Text] [Related]

  • 13. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
    Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, Zhu YJ, Ripley RT, Mathur A, Liu F, Yang M, Meltzer PA, Marquez VE, De Rienzo A, Bueno R, Schrump DS.
    Clin Cancer Res; 2012 Jan 01; 18(1):77-90. PubMed ID: 22028491
    [Abstract] [Full Text] [Related]

  • 14. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
    De Rienzo A, Richards WG, Yeap BY, Coleman MH, Sugarbaker PE, Chirieac LR, Wang YE, Quackenbush J, Jensen RV, Bueno R.
    Clin Cancer Res; 2013 May 01; 19(9):2493-502. PubMed ID: 23493352
    [Abstract] [Full Text] [Related]

  • 15. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I, Comar M, Puozzo A, Stendardo M, Boschetto P, Orecchia S, Libener R, Guaschino R, Pietrobon S, Ferracin M, Negrini M, Martini F, Bovenzi M, Tognon M.
    Oncotarget; 2016 Dec 13; 7(50):82700-82711. PubMed ID: 27716620
    [Abstract] [Full Text] [Related]

  • 16. Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T, Lee D, Wu L, Patel P, Young AJ, Wada H, Hu HP, Ujiie H, Kaji M, Kano S, Matsuge S, Domen H, Kaga K, Matsui Y, Kanno H, Hatanaka Y, Hatanaka KC, Matsuno Y, de Perrot M, Yasufuku K.
    Int J Oncol; 2016 Aug 13; 49(2):448-56. PubMed ID: 27279560
    [Abstract] [Full Text] [Related]

  • 17. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
    Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K.
    Virchows Arch; 2013 Jan 13; 462(1):83-93. PubMed ID: 23187830
    [Abstract] [Full Text] [Related]

  • 18. Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.
    Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reynies A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D.
    Clin Cancer Res; 2017 Jun 15; 23(12):3191-3202. PubMed ID: 28003305
    [Abstract] [Full Text] [Related]

  • 19. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K, Gemma A.
    Oncol Rep; 2014 Dec 15; 32(6):2365-72. PubMed ID: 25231602
    [Abstract] [Full Text] [Related]

  • 20. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
    Linton A, Cheng YY, Griggs K, Schedlich L, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G.
    Br J Cancer; 2014 Jan 21; 110(2):510-9. PubMed ID: 24327015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.